Konstantinos Votanopoulos
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peritoneal Neoplasms | 44 | 2020 | 259 | 12.570 |
Why?
|
| Hyperthermia, Induced | 42 | 2020 | 243 | 12.220 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 31 | 2020 | 155 | 8.290 |
Why?
|
| Appendiceal Neoplasms | 21 | 2020 | 98 | 6.680 |
Why?
|
| Sarcoma | 22 | 2021 | 73 | 6.120 |
Why?
|
| Stomach Neoplasms | 36 | 2019 | 84 | 6.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 24 | 2020 | 458 | 5.460 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2020 | 367 | 5.120 |
Why?
|
| Adenocarcinoma | 33 | 2018 | 308 | 4.320 |
Why?
|
| Survival Rate | 64 | 2020 | 877 | 3.600 |
Why?
|
| Gastrectomy | 29 | 2019 | 68 | 3.470 |
Why?
|
| Antineoplastic Agents | 17 | 2020 | 608 | 3.130 |
Why?
|
| Retrospective Studies | 71 | 2020 | 3509 | 2.890 |
Why?
|
| Prognosis | 62 | 2020 | 1497 | 2.870 |
Why?
|
| Combined Modality Therapy | 35 | 2020 | 560 | 2.820 |
Why?
|
| Neoplasm Staging | 45 | 2019 | 447 | 2.680 |
Why?
|
| Follow-Up Studies | 49 | 2020 | 2265 | 2.630 |
Why?
|
| Adrenocortical Carcinoma | 18 | 2019 | 35 | 2.510 |
Why?
|
| Adrenal Cortex Neoplasms | 18 | 2019 | 36 | 2.500 |
Why?
|
| Organoids | 6 | 2020 | 94 | 2.370 |
Why?
|
| Middle Aged | 107 | 2020 | 11817 | 2.370 |
Why?
|
| Postoperative Complications | 23 | 2020 | 780 | 2.290 |
Why?
|
| Retroperitoneal Neoplasms | 7 | 2020 | 18 | 2.220 |
Why?
|
| Neoplasms | 8 | 2020 | 726 | 2.140 |
Why?
|
| Humans | 142 | 2021 | 32005 | 2.100 |
Why?
|
| Male | 118 | 2020 | 19165 | 2.080 |
Why?
|
| Lymph Node Excision | 11 | 2019 | 89 | 2.030 |
Why?
|
| Female | 118 | 2020 | 19959 | 2.000 |
Why?
|
| Chemotherapy, Adjuvant | 22 | 2019 | 190 | 1.830 |
Why?
|
| Mesothelioma | 5 | 2019 | 39 | 1.670 |
Why?
|
| Aged | 77 | 2020 | 10301 | 1.640 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 2019 | 58 | 1.640 |
Why?
|
| Lymph Nodes | 8 | 2020 | 107 | 1.540 |
Why?
|
| Extremities | 8 | 2020 | 50 | 1.520 |
Why?
|
| Prospective Studies | 23 | 2020 | 2282 | 1.520 |
Why?
|
| Carcinoma | 5 | 2016 | 91 | 1.510 |
Why?
|
| Adult | 65 | 2020 | 9345 | 1.510 |
Why?
|
| Soft Tissue Neoplasms | 6 | 2021 | 39 | 1.440 |
Why?
|
| Colonic Neoplasms | 3 | 2016 | 71 | 1.430 |
Why?
|
| Pancreatectomy | 4 | 2019 | 27 | 1.390 |
Why?
|
| Melanoma | 3 | 2019 | 164 | 1.370 |
Why?
|
| Mitomycin | 7 | 2020 | 51 | 1.240 |
Why?
|
| Adenocarcinoma, Mucinous | 5 | 2020 | 29 | 1.220 |
Why?
|
| Models, Biological | 2 | 2019 | 392 | 1.130 |
Why?
|
| Morbidity | 9 | 2017 | 98 | 1.110 |
Why?
|
| Aged, 80 and over | 30 | 2020 | 3990 | 1.010 |
Why?
|
| Neoadjuvant Therapy | 5 | 2020 | 67 | 0.960 |
Why?
|
| United States | 43 | 2020 | 3939 | 0.950 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2020 | 78 | 0.920 |
Why?
|
| Adrenalectomy | 8 | 2018 | 30 | 0.910 |
Why?
|
| Abdominal Neoplasms | 4 | 2018 | 14 | 0.870 |
Why?
|
| Treatment Outcome | 25 | 2020 | 3306 | 0.860 |
Why?
|
| Colorectal Neoplasms | 8 | 2020 | 215 | 0.860 |
Why?
|
| Splenectomy | 4 | 2019 | 21 | 0.840 |
Why?
|
| Young Adult | 18 | 2020 | 2636 | 0.830 |
Why?
|
| Peritoneum | 4 | 2020 | 33 | 0.820 |
Why?
|
| Survival Analysis | 15 | 2020 | 483 | 0.780 |
Why?
|
| Registries | 3 | 2018 | 298 | 0.720 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 16 | 0.710 |
Why?
|
| Skin Neoplasms | 2 | 2019 | 214 | 0.710 |
Why?
|
| Databases, Factual | 12 | 2020 | 355 | 0.690 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2019 | 56 | 0.680 |
Why?
|
| Liver Neoplasms | 3 | 2018 | 155 | 0.660 |
Why?
|
| Organoplatinum Compounds | 3 | 2013 | 46 | 0.630 |
Why?
|
| Intensive Care Units | 2 | 2015 | 110 | 0.610 |
Why?
|
| Quality of Life | 7 | 2020 | 946 | 0.600 |
Why?
|
| Diaphragm | 2 | 2014 | 39 | 0.590 |
Why?
|
| Intestinal Perforation | 1 | 2016 | 9 | 0.570 |
Why?
|
| Lymphatic Metastasis | 12 | 2018 | 166 | 0.560 |
Why?
|
| Cell Proliferation | 1 | 2018 | 604 | 0.530 |
Why?
|
| Linitis Plastica | 1 | 2015 | 2 | 0.530 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 96 | 0.520 |
Why?
|
| Peritoneal Stomata | 1 | 2015 | 3 | 0.520 |
Why?
|
| Patient Admission | 1 | 2015 | 60 | 0.510 |
Why?
|
| Immunotherapy | 3 | 2020 | 81 | 0.500 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2014 | 12 | 0.480 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 40 | 0.480 |
Why?
|
| Abdominal Cavity | 1 | 2014 | 5 | 0.480 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 881 | 0.470 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 31 | 0.470 |
Why?
|
| Gallbladder Neoplasms | 1 | 2014 | 34 | 0.470 |
Why?
|
| Laparoscopy | 3 | 2019 | 172 | 0.450 |
Why?
|
| Length of Stay | 6 | 2020 | 314 | 0.450 |
Why?
|
| Reoperation | 6 | 2017 | 226 | 0.450 |
Why?
|
| Ascites | 1 | 2013 | 16 | 0.450 |
Why?
|
| Urinary Tract | 1 | 2013 | 22 | 0.450 |
Why?
|
| Urologic Diseases | 1 | 2013 | 27 | 0.450 |
Why?
|
| Rectal Neoplasms | 1 | 2013 | 18 | 0.430 |
Why?
|
| Nomograms | 3 | 2020 | 32 | 0.430 |
Why?
|
| Infusions, Parenteral | 5 | 2016 | 65 | 0.430 |
Why?
|
| Feasibility Studies | 3 | 2019 | 293 | 0.420 |
Why?
|
| Adolescent | 9 | 2020 | 3539 | 0.410 |
Why?
|
| Neutrophils | 3 | 2020 | 106 | 0.390 |
Why?
|
| Risk Factors | 14 | 2020 | 3876 | 0.380 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 411 | 0.380 |
Why?
|
| Hepatectomy | 3 | 2018 | 56 | 0.380 |
Why?
|
| Disease-Free Survival | 11 | 2019 | 317 | 0.360 |
Why?
|
| Vena Cava, Inferior | 1 | 2009 | 30 | 0.340 |
Why?
|
| Abdominal Injuries | 1 | 2009 | 31 | 0.340 |
Why?
|
| Cisplatin | 3 | 2014 | 76 | 0.340 |
Why?
|
| Cystadenoma | 1 | 2009 | 2 | 0.340 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2009 | 10 | 0.330 |
Why?
|
| Wounds, Gunshot | 1 | 2009 | 34 | 0.330 |
Why?
|
| Radiography, Thoracic | 2 | 2019 | 45 | 0.330 |
Why?
|
| Abdominal Pain | 1 | 2009 | 44 | 0.330 |
Why?
|
| Lymphocytes | 2 | 2020 | 57 | 0.300 |
Why?
|
| Patient Readmission | 4 | 2016 | 126 | 0.300 |
Why?
|
| Perfusion | 2 | 2020 | 73 | 0.300 |
Why?
|
| Propoxur | 1 | 2007 | 1 | 0.290 |
Why?
|
| Cohort Studies | 12 | 2019 | 1817 | 0.290 |
Why?
|
| Psychomotor Performance | 1 | 2008 | 99 | 0.290 |
Why?
|
| Insecticides | 1 | 2007 | 21 | 0.290 |
Why?
|
| Child | 4 | 2014 | 2438 | 0.290 |
Why?
|
| Pancreatitis | 1 | 2007 | 22 | 0.290 |
Why?
|
| General Surgery | 1 | 2008 | 88 | 0.280 |
Why?
|
| Propensity Score | 4 | 2019 | 39 | 0.280 |
Why?
|
| Proportional Hazards Models | 9 | 2020 | 753 | 0.280 |
Why?
|
| Obesity | 2 | 2014 | 1175 | 0.270 |
Why?
|
| Multivariate Analysis | 5 | 2015 | 684 | 0.270 |
Why?
|
| Preoperative Care | 4 | 2015 | 114 | 0.270 |
Why?
|
| Neoplasm Invasiveness | 6 | 2017 | 190 | 0.270 |
Why?
|
| Blood Transfusion | 2 | 2017 | 73 | 0.270 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 128 | 0.270 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2015 | 6 | 0.250 |
Why?
|
| Body Mass Index | 3 | 2020 | 923 | 0.240 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.230 |
Why?
|
| Blood Platelets | 2 | 2015 | 39 | 0.230 |
Why?
|
| North Carolina | 3 | 2016 | 1514 | 0.230 |
Why?
|
| Carboplatin | 2 | 2013 | 48 | 0.220 |
Why?
|
| Limb Salvage | 2 | 2020 | 22 | 0.220 |
Why?
|
| Risk Assessment | 3 | 2018 | 1426 | 0.220 |
Why?
|
| Pesticides | 1 | 2016 | 199 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2016 | 232 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 290 | 0.210 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 244 | 0.210 |
Why?
|
| Cell Survival | 2 | 2019 | 284 | 0.190 |
Why?
|
| Case-Control Studies | 3 | 2016 | 898 | 0.180 |
Why?
|
| Health Status | 3 | 2019 | 399 | 0.180 |
Why?
|
| Leukocyte Count | 1 | 2020 | 49 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 918 | 0.180 |
Why?
|
| Neoplasm, Residual | 2 | 2016 | 25 | 0.170 |
Why?
|
| Patient Selection | 2 | 2020 | 276 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 940 | 0.170 |
Why?
|
| Meta-Analysis as Topic | 1 | 2019 | 43 | 0.170 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 220 | 0.160 |
Why?
|
| Incidental Findings | 1 | 2018 | 25 | 0.160 |
Why?
|
| Thoracic Neoplasms | 1 | 2018 | 5 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 170 | 0.160 |
Why?
|
| Rare Diseases | 1 | 2018 | 21 | 0.160 |
Why?
|
| Interinstitutional Relations | 1 | 2018 | 12 | 0.160 |
Why?
|
| Thorax | 1 | 2018 | 29 | 0.160 |
Why?
|
| Caregivers | 1 | 2020 | 114 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 201 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2019 | 545 | 0.150 |
Why?
|
| Age Factors | 5 | 2020 | 1188 | 0.150 |
Why?
|
| Incidence | 6 | 2016 | 1199 | 0.150 |
Why?
|
| Anesthesia, Conduction | 1 | 2018 | 25 | 0.150 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 81 | 0.150 |
Why?
|
| Hospital Mortality | 2 | 2016 | 198 | 0.140 |
Why?
|
| Esophagogastric Junction | 1 | 2017 | 7 | 0.140 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 35 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 510 | 0.140 |
Why?
|
| Tumor Burden | 4 | 2017 | 58 | 0.140 |
Why?
|
| Depression | 1 | 2020 | 444 | 0.140 |
Why?
|
| Mitotane | 1 | 2015 | 2 | 0.130 |
Why?
|
| Gastric Stump | 1 | 2015 | 2 | 0.130 |
Why?
|
| Helicobacter Infections | 1 | 2015 | 9 | 0.130 |
Why?
|
| Abdomen | 1 | 2016 | 43 | 0.130 |
Why?
|
| Gastroenterostomy | 1 | 2015 | 2 | 0.130 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2015 | 6 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 42 | 0.130 |
Why?
|
| Jejunostomy | 1 | 2015 | 8 | 0.130 |
Why?
|
| Esophagectomy | 1 | 2015 | 15 | 0.130 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 52 | 0.130 |
Why?
|
| Forecasting | 1 | 2016 | 143 | 0.130 |
Why?
|
| Enteral Nutrition | 1 | 2015 | 30 | 0.130 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 412 | 0.130 |
Why?
|
| Odds Ratio | 4 | 2020 | 472 | 0.130 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 876 | 0.120 |
Why?
|
| Anemia | 1 | 2015 | 58 | 0.120 |
Why?
|
| Intraoperative Care | 1 | 2015 | 48 | 0.120 |
Why?
|
| Drainage | 1 | 2015 | 72 | 0.120 |
Why?
|
| Cardia | 1 | 2014 | 1 | 0.120 |
Why?
|
| Skilled Nursing Facilities | 1 | 2014 | 11 | 0.120 |
Why?
|
| Time Factors | 2 | 2017 | 2149 | 0.120 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2014 | 9 | 0.120 |
Why?
|
| Injections, Intraperitoneal | 1 | 2014 | 45 | 0.120 |
Why?
|
| Frozen Sections | 1 | 2014 | 18 | 0.120 |
Why?
|
| Colectomy | 1 | 2014 | 24 | 0.120 |
Why?
|
| Omentum | 1 | 2014 | 24 | 0.120 |
Why?
|
| Pneumonia | 1 | 2014 | 68 | 0.120 |
Why?
|
| Appendix | 1 | 2014 | 4 | 0.120 |
Why?
|
| Thrombosis | 1 | 2014 | 73 | 0.120 |
Why?
|
| Respiratory Insufficiency | 1 | 2014 | 57 | 0.120 |
Why?
|
| Thiosulfates | 1 | 2013 | 3 | 0.120 |
Why?
|
| Endosonography | 1 | 2014 | 56 | 0.120 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2013 | 12 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 89 | 0.110 |
Why?
|
| Ovariectomy | 1 | 2014 | 166 | 0.110 |
Why?
|
| Logistic Models | 4 | 2018 | 781 | 0.110 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2015 | 198 | 0.110 |
Why?
|
| Patient Discharge | 1 | 2014 | 188 | 0.110 |
Why?
|
| Ethnic Groups | 1 | 2016 | 476 | 0.110 |
Why?
|
| Disease Progression | 1 | 2014 | 594 | 0.100 |
Why?
|
| Analysis of Variance | 2 | 2015 | 463 | 0.100 |
Why?
|
| European Continental Ancestry Group | 1 | 2016 | 1166 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 288 | 0.100 |
Why?
|
| Liver | 2 | 2015 | 484 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2011 | 86 | 0.090 |
Why?
|
| Ligation | 1 | 2009 | 56 | 0.090 |
Why?
|
| Amputation | 1 | 2009 | 38 | 0.090 |
Why?
|
| Leg | 1 | 2009 | 65 | 0.080 |
Why?
|
| Compartment Syndromes | 1 | 2009 | 39 | 0.080 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2009 | 6 | 0.080 |
Why?
|
| Lymphocyte Count | 2 | 2020 | 24 | 0.080 |
Why?
|
| Mediastinal Cyst | 1 | 2007 | 3 | 0.080 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 95 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 517 | 0.070 |
Why?
|
| Administration, Inhalation | 1 | 2007 | 54 | 0.070 |
Why?
|
| Fluid Therapy | 1 | 2007 | 24 | 0.070 |
Why?
|
| Mental Health | 2 | 2019 | 117 | 0.070 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2008 | 86 | 0.070 |
Why?
|
| Genetic Markers | 2 | 2018 | 124 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 2008 | 127 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2008 | 220 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 322 | 0.070 |
Why?
|
| Blood Loss, Surgical | 2 | 2015 | 49 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2008 | 313 | 0.060 |
Why?
|
| Rectal Diseases | 1 | 2002 | 2 | 0.050 |
Why?
|
| Cysts | 1 | 2002 | 17 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2020 | 72 | 0.040 |
Why?
|
| Immune System Phenomena | 1 | 2020 | 5 | 0.040 |
Why?
|
| Intestinal Obstruction | 1 | 2020 | 11 | 0.040 |
Why?
|
| Oncogenes | 1 | 2020 | 13 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 126 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 70 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2020 | 147 | 0.040 |
Why?
|
| Palliative Care | 1 | 2020 | 52 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2020 | 123 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 24 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2020 | 100 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2019 | 70 | 0.040 |
Why?
|
| Retroperitoneal Space | 1 | 2018 | 20 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 111 | 0.040 |
Why?
|
| Wound Healing | 1 | 2020 | 185 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2019 | 118 | 0.040 |
Why?
|
| Hydrogels | 1 | 2019 | 121 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2018 | 29 | 0.040 |
Why?
|
| Appendectomy | 1 | 2018 | 16 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2020 | 282 | 0.040 |
Why?
|
| Health Services Research | 1 | 2018 | 82 | 0.040 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 28 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 58 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 164 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 158 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 726 | 0.040 |
Why?
|
| Inflammation | 1 | 2020 | 530 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 582 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2017 | 116 | 0.030 |
Why?
|
| Emotions | 1 | 2016 | 58 | 0.030 |
Why?
|
| Pancreatic Fistula | 1 | 2016 | 3 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 97 | 0.030 |
Why?
|
| Helicobacter pylori | 1 | 2015 | 8 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 245 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 16 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 23 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2015 | 57 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 125 | 0.030 |
Why?
|
| Stomach | 1 | 2015 | 15 | 0.030 |
Why?
|
| Colon | 1 | 2015 | 51 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2016 | 350 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 236 | 0.030 |
Why?
|
| Spleen | 1 | 2015 | 87 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 35 | 0.030 |
Why?
|
| Pancreas | 1 | 2015 | 103 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 84 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2014 | 54 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 566 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2019 | 656 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 20 | 0.020 |
Why?
|
| Track and Field | 1 | 2007 | 3 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 376 | 0.020 |
Why?
|
| Rectum | 1 | 2002 | 17 | 0.010 |
Why?
|